We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Sealant Shown to Reduce Postsurgical Adhesions

By HospiMedica staff writers
Posted on 25 Jun 2002
A clinical trial in Europe involving 21 babies with heart defects has shown that a synthetic sealant significantly reduced postsurgical adhesions when compared to controls.

The clinical trial involved newborn babies with congenital heart defects requiring surgery and a second follow-up surgery as part of their routine treatment. More...
This allows surgeons to determine whether adhesions were significantly reduced or prevented. The sealant, called CoSeal, was used in 14 newborns with complex congenital heart defects and eight have returned for follow-up surgical procedures. CoSeal substantially reduced adhesions compared to control patients.

CoSeal is a synthetic, self-polymerizing liquid biomaterial that can be prepared in one minute and resorbs in less than 30 days. Because it is synthetic, the risks of disease transmission associated with blood products are eliminated. CoSeal adheres to tissue where it is applied and remains in place during the critical wound-healing period. It is now being marketed in some countries as a vascular sealant, says the developer, Cohesion Technologies, Inc. (Palo Alto, CA, USA).

"My colleagues and I were astounded when we opened the child during a follow-up surgery and saw that only minor adhesions had formed as a result of the previous surgery,” said Dr. Jianshi Liu, heart surgeon, Charite Hospital (Berlin, Germany).




Related Links:
Cohesion

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.